Table 3.
Summary of effects of biologics on bone biochemical marker in RA
| Biologics | Classification | Bone formation marker | Bone resorption marker | Others | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| PINP | OC | BAP | CTX | NTX | ICTP | DPD | OPG | RANKL | OPG/RANKL | MMP3 | DKK1 | ||||
| Infliximab | TNF-α inhibitor | ↑ | ↑ | → | ↓ | ↓ | ↓ | ↓ | ↑ | ↓ | ↓ | ||||
| Adalimumab | TNF-α inhibitor | ↑ | ↓ | ↑ | |||||||||||
| Golimumab | TNF-α inhibitor | ↑ | ↓ | ↑ | |||||||||||
| Certolizumab | TNF-α inhibitor | ↑ | ↓ | ↑ | ↓ | ||||||||||
| Etanercept | TNF-α inhibitor | ↑ | ↑ | ↑ | ↓ | → | ↑→ | ↓→ | ↓ | ↓ | |||||
| Abatacept | CTLA4-Ig | ↑ | ↓ | ↓ | |||||||||||
| Rituximab | Anti-CD20 | ↑ | ↑ | ↓ | ↓ | ↑ | |||||||||
| Tocilizumab | IL-6 inhibitor | ↑ | ↓ | ↑ | ↑ | ↓ | ↓ | ||||||||